Highlights
• $12M equity funding facility secured
• Second European patent secured for CVac™ ovarian cancer treatment
• Commencement of patient treatment with CVac™ Cancer Therapy Vaccine
• Completion of first Share Purchase Plan
• Continuing towards US FDA approvals process for CVac™
• Progressing commercialisation of CVac™ in Australia
• Success of fellow cancer immune-therapy development company, Nasdaq-listed
Dendreon
______________________________________________________________________________
Highlights• $12M equity funding facility secured• Second...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
0.015(4.69%) |
Mkt cap ! $479.3M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.5¢ | 32.0¢ | $755.8K | 2.316M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 342891 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 89717 | 8 |
View Market Depth
| Last trade - 12.45pm 25/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |